Browsing Tag
DAYBUE
3 posts
Neuren Pharmaceuticals (ASX: NEU) jumped 45% in two sessions, but how much DAYBUE upside remains?
DAYBUE’s EU breakthrough sent NEU up 45% in two sessions. The harder test is whether royalties and NNZ-2591 justify A$2.25 billion.
Acadia’s LOTUS study confirms long‑term benefits and manageable side‑effects of DAYBUE over 12 months in Rett syndrome
New real-world data shows DAYBUE improves Rett syndrome symptoms and is tolerable over 12 months. Find out what the LOTUS study reveals for patients and doctors.
Neuren Pharmaceuticals advances NNZ-2591 for Phelan-McDermid syndrome to Phase 3 clinical trial
Neuren Pharmaceuticals has secured approval from the United States Food and Drug Administration (FDA) to progress into the…